Dr. Gradishar Discusses Dual HER2-Targeting in Breast Cancer
William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses dual HER2-targeting in breast cancer.
William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses dual HER2-targeting in breast cancer.
Trastuzumab (Herceptin) is used in different settings in the treatment of patients with HER2-positive breast cancer.
There is a trend forming, says Gradishar, as dual HER2-targeting is being used first in the preoperative, postoperative, and early in the sequence for patients with metastatic disease.
